In 2002, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) found that in a hypertensive population with at least one additional coronary heart disease (CHD) risk factor, randomization to chlorthalidone (thiazide-type diuretic), amlodpine (calcium channel blocker [CCB]), or lisinopril (angiotensin-converting enzyme inhibitor [ACE-I]) was associated with similar rates of coronary heart disease outcomes [1].Chlorthalidone was associated with a lower risk of heart failure, a secondary outcome. Here, ACE is linked to coronary artery disorder.